Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy

Phase 2

Recruiting

Conditions: Relapsed Follicular Lymphoma
Refractory Follicular Lymphoma

Interventions: Drug: Epcoritamab
Drug: Investigation agent 2
Drug: Investigation agent 3
Drug: Lenalidomide
Drug: Rituximab
Drug: Obinutuzumab
Drug: Bendamustine
Drug: Vincristine
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Prednisone

First Posted Date: 2023-05-08

Last Posted Date: 2023-11-29

Lead Sponsor: University of Birmingham

Target Recruit Count: 284

Registration Number: NCT05848765

Locations: 🇬🇧
Cardiff and vale University LHB, Cardiff, United Kingdom
🇬🇧
Belfast Health & Social Care Trust, Belfast, United Kingdom
🇬🇧
NHS Grampian, Aberdeen, United Kingdom

and more 22 locations

Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant

Phase 1

Recruiting

Conditions: Hematologic Malignancies

Interventions: Drug: Cyclophosphamide

First Posted Date: 2023-05-08

Last Posted Date: 2024-08-21

Lead Sponsor: Ronald Paquette

Target Recruit Count: 26

Registration Number: NCT05849207

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome

Phase 2

Recruiting

Conditions: Aneurysm
Behcet Syndrome, Vascular Type

Interventions: Drug: tocilizumab
Drug: tofacitinib
Drug: cyclophosphamide

First Posted Date: 2023-05-06

Last Posted Date: 2024-08-19

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 81

Registration Number: NCT05845723

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

Allo HSCT Using RIC and PTCy for Hematological Diseases

Phase 2

Recruiting

Conditions: Plasma Cell Leukemia
Biphenotypic Acute Leukemia
Prolymphocytic Leukemia
Leukemia, Myeloid
Acute Lymphocytic Leukemia
Chronic Myelogenous Leukemia
Myelodysplastic Syndromes
Acute Myelogenous Leukemia
Undifferentiated Leukemia
Myelodysplastic Syndrome With Excess Blasts-1

Interventions: Biological: Peripheral Blood Stem Cell Transplant
Drug: Allopurinol 300 MG
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: Bone Marrow Cell Transplant
Radiation: Total Body Irradiation
Drug: Sirolimus Pill
Drug: Mycophenolate Mofetil

First Posted Date: 2023-04-10

Last Posted Date: 2024-05-07

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 56

Registration Number: NCT05805605

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients with High-risk Diffuse Large B-cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Lymphoma
Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: Glofitamab
Drug: Polatuzumab
Drug: Rituximab
Drug: Doxorubicin Hydrochloride
Drug: Cyclophosphamide
Drug: Prednisone

First Posted Date: 2023-04-05

Last Posted Date: 2024-12-18

Lead Sponsor: Jennifer Crombie, MD

Target Recruit Count: 41

Registration Number: NCT05800366

Locations: 🇺🇸
University of Miami Sylvester Cancer Center, Miami, Florida, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States